

Supporting Information

Wright et al. 10.1073/pnas.1501698112




Fig. S1. Size-exclusion chromatograms of purified α -helical (A) and nuclease (B) lobes. After cleavage of the affinity tag by TEV protease and further clean-up using ortho-Ni-NTA and ion-exchange columns (α -helical lobe) or an ortho-Ni-NTA column alone (nuclease lobe), the polypeptides were concentrated and injected onto a HiLoad 16/60 Superdex 200 gel filtration column. The α -helical (77 kDa) and nuclease lobes (81 kDa) eluted at 88.4 mL and 76.8 mL, respectively. Both polypeptides were soluble and exhibited consistent activity across multiple rounds of freeze-thawing.




Fig. 56. Strategy for inducible control of genome engineering by a split-Cas9 enzyme complex. (A) Because the α -helical and nuclease lobes dimerize in the presence of sgRNA, both WT and split-Cas9 are functional genome editing tools in cells using full-length sgRNA. (B) sgRNA variants with 3'-hairpin truncations have substantially weaker affinity for the nuclease lobe and thus do not efficiently assemble a functional split-Cas9 complex, leading to an inactive enzyme. In contrast, *in vitro* DNA cleavage by WT Cas9 is minimally affected by these truncations, indicating that the intrinsic activity of the Cas9-sgRNA enzyme complex does not require hairpins at the 3' end. (C) We propose an inducible split-Cas9 system, in which exogenous dimerization domains control the assembly of a functional ternary complex between a 3'-truncated sgRNA and the α -helical and nuclease lobes. By fusing both lobes to domains that dimerize only upon some external stimulus (e.g., a small molecule; red trapezoid), split-Cas9 can be specifically activated for a desired genome-engineering outcome.

Table S2. DNA and RNA substrates used in this study

Description	Sequence*	Used in Figs.
λ1 target dsDNA	5′-AGCAGAAATCTCTGCTGACGCATAAAGATGAGACGCTGGAGTACAAACGTCAGCT-3′ 3′-TCGTCTTTAGAGACGACTGCGTATTTCTACTCTGCGACCTCATGTTTGCAGTCGA-5′	1D, 3C, S2A, S2B, S3, S5, S7
λ1 target dsDNA, mutated PAM	5′-AGCAGAAATCTCTGCTGACGCATAAAGATGAGACGCTCGAGTACAAACGTCAGCT-3′ 3′-TCGTCTTTAGAGACGACTGCGTATTTCTACTCTGCGAGCTCATGTTTGCAGTCGA-5′	S2C
λ2 target dsDNA, (λ1 mismatch)	5′-GAGTGGAAAGGATGCCAGTGATAAGTGGAAATGCCATGTGGGCTGTCAAATTTGAGC-3′ 3′-CTCACCTTCCTACGGTCACTATTCACCTTACGGTACACCCGACAGTTTAACTCG-5′	S2C
λ1 sgRNA, full-length	5′-GACGCAUAAAGAUGAGACGCGUUUUAGAGCUAUGCUGUUUUGGAAACAAAACAGCAU- AGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUG- CUUUUUUUGGAUC-3′	1D, 2C, 2E, 3C, S2A, S2C, S3, S4D, S5, S7A
λ1 crRNA	5′-GACGCAUAAAGAUGAGACGCGUUUUAGAGCUAUGCUGUUUUG-3′	2E, S2B
TracrRNA	5′-GGACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCAC- CGAGUCGGUGCUUUUU-3′	2E, S2B
λ1 sgRNA, Δhairpin1 and -2	5′-GACGCAUAAAGAUGAGACGCGUUUUAGAGCUAUGCUGUUUUGGAAACAAAACAGCAU- AGCAAGUUAAAAUAAGGCUAGUCCGUGGAUC-3′	2D, 3C, S7A
λ1 sgRNA, Δhairpin2	5′-GACGCAUAAAGAUGAGACGCGUUUUAGAGCUAUGCUGUUUUGGAAACAAAACAGCAU- AGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGAUC-3′	S7B
λ1 sgRNA, Δhairpin1	5′-GACGCAUAAAGAUGAGACGCGUUUUAGAGCUAUGCUGUUUUGGAAACAAAACAGCAU- AGCAAGUUAAAAUAAGGCUAGUCCGUUGGCACCGAGUCGGUGCUUUUUUU-3′	S7B
λ1 sgRNA, Δspacer-nexus	5′-GGUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU-3′	2D
EMX1 sgRNA, full-length	5′-GGUACCUCCAUGACUAGGGGUUUUAGAGCUAUGCUGGAAACAGCAUAGCAAGUUU- AAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU-3′	3B

*RNA guide sequences and complementary DNA target strand sequences are shown in red; PAM sites are highlighted in yellow.